Edwards Lifesciences Stock Revenue

EWL Stock  EUR 70.08  0.26  0.37%   
Edwards Lifesciences fundamentals help investors to digest information that contributes to Edwards Lifesciences' financial success or failures. It also enables traders to predict the movement of Edwards Stock. The fundamental analysis module provides a way to measure Edwards Lifesciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Edwards Lifesciences stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Edwards Lifesciences Company Revenue Analysis

Edwards Lifesciences' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.

Revenue

 = 

Money Received

-

Discounts and Returns

More About Revenue | All Equity Analysis

Current Edwards Lifesciences Revenue

    
  5.38 B  
Most of Edwards Lifesciences' fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Edwards Lifesciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Competition

Based on the latest financial disclosure, Edwards Lifesciences reported 5.38 B of revenue. This is 29.43% lower than that of the Healthcare sector and 111.01% higher than that of the Medical Devices industry. The revenue for all Germany stocks is 42.95% higher than that of the company.

Edwards Revenue Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Edwards Lifesciences' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Edwards Lifesciences could also be used in its relative valuation, which is a method of valuing Edwards Lifesciences by comparing valuation metrics of similar companies.
Edwards Lifesciences is rated below average in revenue category among its peers.

Edwards Fundamentals

About Edwards Lifesciences Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Edwards Lifesciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Edwards Lifesciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Edwards Lifesciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Other Information on Investing in Edwards Stock

Edwards Lifesciences financial ratios help investors to determine whether Edwards Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Edwards with respect to the benefits of owning Edwards Lifesciences security.